Zimmer Biomet Q2 2020 Earnings Report
Key Takeaways
Zimmer Biomet's second quarter net sales were $1.226 billion, a decrease of 38.3% from the prior year period. The company reported a net loss of $206.6 million, with a diluted loss per share of $1.00. Adjusted diluted earnings per share were $0.05, a decrease of 97.4% from the prior year period.
Second quarter net sales decreased 38.3% to $1.226 billion, and decreased 38.0% on a constant currency basis.
Second quarter diluted loss per share was $1.00; adjusted diluted earnings per share were $0.05.
COVID-19 significantly impacted second quarter performance due to global decline in elective procedure volumes.
Company continues to invest in primary growth initiatives and innovative R&D programs.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Forward Guidance
Zimmer Biomet is currently unable to quantify the expected impact on its results of operations, financial condition and cash flows for 2020 and is not providing full-year financial guidance at this time due to the uncertainty around the scope and duration of COVID-19.
Revenue & Expenses
Visualization of income flow from segment revenue to net income